Shorla Phar­ma scores an ex­pe­dit­ed re­view for its mys­tery can­di­date to treat T-cell ma­lig­nan­cies

Since launch­ing Shorla Phar­ma three years ago to de­sign bet­ter ver­sions of ex­ist­ing can­cer drugs, co-founders Sharon Cun­ning­ham and Or­laith Ryan have of­fered scarce de­tails on what it is they’re work­ing on. But the FDA clear­ly likes what it sees.

The agency has grant­ed pri­or­i­ty re­view to SH-111, Shorla’s mys­tery can­di­date for the third-line treat­ment of adults and chil­dren with T-cell acute lym­phoblas­tic leukemia (T-ALL) and T-cell lym­phoblas­tic lym­phoma (T-LBL), the com­pa­ny said on Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER